COMP <GO>
ELV vs ABBV // PIOTROSKI F-SCORE QUALITY
Elevance Health Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: ELV 6
— ABBV 8
■ METRIC PARITY
LAST: $420.07 (-0.46%) • MKT CAP: $91.18B
piotroski-score
7/9
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ELV VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ELV | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 89.40% | 70.20% | +19.20 | ELV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.70% | 29.00% | -20.30 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 13.8x | 33.3x | -19.50 | ELV | /valuation <GO> |
| Free Cash Flow Yield | 3.48% | 3.47% | +0.01 | ELV | /fcf-yield <GO> |
| Operating Margin | 3.60% | 24.60% | -21.00 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 2.80% | 6.90% | -4.10 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 12.50% | 8.60% | +3.90 | ELV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.68% | 2.27% | -0.59 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.17 | 5.33 | -2.16 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 7.40% | -0.30 | ELV | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.8 | 72.8 | -22.01 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 1.15 | -0.08 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 13.5x | 113.1x | -99.60 | ELV | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $91.18B | $513.86B | -$422.68B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ELV REV | ABBV REV | ELV GROSS % | ABBV GROSS % | ELV FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $199.13B | $61.16B | 89.4% | 70.2% | $3.17B | $17.82B |
| FY 2024 | $177.01B | $56.33B | 88.8% | 70.0% | $4.55B | $17.83B |
| FY 2023 | $171.34B | $54.32B | 44.0% | 44.0% | $350.7M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ELV // BETA 1.07
ABBV // BETA 1.15